Tryptophan Metabolites and Brain Disorders
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 378879111 | ||
| 003 | CHVBK | ||
| 005 | 20180305123427.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 161128e20030721xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1515/CCLM.2003.129 |2 doi |
| 035 | |a (NATIONALLICENCE)gruyter-10.1515/CCLM.2003.129 | ||
| 245 | 0 | 0 | |a Tryptophan Metabolites and Brain Disorders |h [Elektronische Daten] |c [Trevor W. Stone, Gillian M. Mackay, Caroline M. Forrest, Catherine J. Clark, L. Gail Darlington] |
| 520 | 3 | |a Tryptophan is metabolised primarily along the kynurenine pathway, of which two components are now known to have marked effects on neurons in the central nervous system. Quinolinic acid is an agonist at the population of glutamate receptors which are sensitive to N-methyl-D-aspartate (NMDA), and kynurenic acid is an antagonist at several glutamate receptors. Consequently quinolinic acid can act as a neurotoxin while kynurenic acid is neuroprotectant. A third kynurenine, 3-hydroxykynurenine, can generate free radicals and contribute to, or exacerbate, neuronal damage. Changes in the absolute or relative concentrations of these kynurenines have been implicated in a variety of central nervous system disorders such as the AIDS-dementia complex and Huntington's disease, raising the possibility that interference with their actions or synthesis could lead to new forms of pharmacotherapy for these conditions. | |
| 540 | |a Copyright © 2003 by Walter de Gruyter GmbH & Co. KG | ||
| 690 | 7 | |a Medical equipment & techniques |2 nationallicence | |
| 690 | 7 | |a Medical diagnosis |2 nationallicence | |
| 690 | 7 | |a Diseases & disorders |2 nationallicence | |
| 700 | 1 | |a Stone |D Trevor W. |4 aut | |
| 700 | 1 | |a Mackay |D Gillian M. |4 aut | |
| 700 | 1 | |a Forrest |D Caroline M. |4 aut | |
| 700 | 1 | |a Clark |D Catherine J. |4 aut | |
| 700 | 1 | |a Darlington |D L. Gail |4 aut | |
| 773 | 0 | |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/7(2003-07-21), 852-859 |x 1434-6621 |q 41:7<852 |1 2003 |2 41 |o cclm | |
| 856 | 4 | 0 | |u https://doi.org/10.1515/CCLM.2003.129 |q text/html |z Onlinezugriff via DOI |
| 908 | |D 1 |a research article |2 jats | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1515/CCLM.2003.129 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Stone |D Trevor W. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Mackay |D Gillian M. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Forrest |D Caroline M. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Clark |D Catherine J. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Darlington |D L. Gail |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/7(2003-07-21), 852-859 |x 1434-6621 |q 41:7<852 |1 2003 |2 41 |o cclm | ||
| 900 | 7 | |b CC0 |u http://creativecommons.org/publicdomain/zero/1.0 |2 nationallicence | |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-gruyter | ||